Document Detail


Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
MedLine Citation:
PMID:  17335544     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To examine retrospectively the relationship between DPD phenotype/genotype and the intensity of 5FU toxicity. METHODS: One hundred and thirty-one case-reports (81 women, 50 men) with 5FU-related toxicity were analyzed. RESULTS: The lower the DPD activity (10-504 pmol min(-1) mg(-1)), the higher the toxicity grade was scored (P < 0.01). Toxicity-related deaths occurred in nine patients (eight women) who significantly expressed lower DPD activity than other patients. Two of the deceased patients had normal DPD activity. The IVS14+1G>A mutation, analyzed in 93 patients, was detected in two patients (nonlethal toxicity). CONCLUSIONS: The IVS14+1G>A mutation may not help prevent toxicity and patients with normal DPD activity may develop life-threatening 5FU toxicity.
Authors:
Nicolas Magné; Marie-Christine Etienne-Grimaldi; Laurent Cals; Nicole Renée; Jean-Louis Formento; Mireille Francoual; Gérard Milano
Related Documents :
8967754 - Deficiency of complex ii of the mitochondrial respiratory chain in late-onset optic atr...
20402744 - Efns guidelines on the diagnostic approach to pauci- or asymptomatic hyperckemia.
14765544 - Identification of a common mutation (gly194cys) in both arab moslem and ashkenazi jewis...
2676634 - Epidemiology and genetics of primary congenital glaucoma in slovakia. description of a ...
21165964 - Further observations on the role of staphylococcus aureus exotoxins and ige in the path...
3292044 - Inhibition of e rosetting and of okt 11 in patients with oral dysplasia and neoplasia.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2007-03-01
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  64     ISSN:  0306-5251     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-19     Completed Date:  2007-12-12     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  237-40     Citation Subset:  IM    
Affiliation:
Institut Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / adverse effects*
Antineoplastic Agents / administration & dosage*,  adverse effects
Dihydrouracil Dehydrogenase (NADP) / administration & dosage*,  adverse effects
Female
Fluorouracil / adverse effects*
Humans
Male
Middle Aged
Mutation, Missense / drug effects*
Polymorphism, Genetic
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 51-21-8/Fluorouracil; EC 1.3.1.2/Dihydrouracil Dehydrogenase (NADP)
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis...
Next Document:  Age dependent systemic exposure to inhaled salbutamol.